Abstract
The title compound 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl)benzyl]}-3-phenyl-3H-pyrrolo[2,3-c]quinoline 1, a compound that showed cytotoxic potential against two leukemia cell lines, has been synthesized via a multi-step pathway. This compound was characterized by single-crystal X-ray diffraction, IR, MS, elemental analysis, 1H and 13C NMR. The crystal (C37H33H5O, Mr = 563.68) belongs to orthorhombic, space group Pbcn with cell parameters a = 30.198(2) Å, b = 12.5097(11) Å, c = 15.6648(13) Å, V = 5917.7(8) Å3, Z = 8, Dc = 1.265 g/cm3, CuKα radiation, λ = 1.54180 Å, µ = 0.611 mm−1, F(000) = 2384, the final R = 0.0491 and wR = 0.1585 for 5698 observed reflections with I > 2σ(I).
Graphical Abstract
The antileukemial 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl)benzyl]}-3-phenyl-3H-pyrrolo[2,3-c]quinoline was synthesized and characterized by X-ray crystallography.
References
Lichtman MA (2008) Oncologist 13:126
Carroll AR, Duffy S, Avery VM (2010) J Org Chem 75:8291
Okanya PW, Mohr KI, Gerth K, Jansen R, Mueller R (2011) J Nat Prod 74:603
Mhaske SB, Lande JR (2013) WO 2013117986
Campos Aguiar AC, Panciera M, Simao dos Santos EF, Singh MK, Garcia ML, Eduardo de Souza G, Nakabashi M, Costa JL, Garcia CRS, Oliva G, Roque Duarte Correia C, Carvalho Guido RV (2018) J Med Chem 61:5547
Akula M, Sridevi JP, Yogeeswari P, Sriram D, Bhattacharya A (2014) Monatsh Chem 145:811
Panarese JD, Lindsley CW (2012) Org Lett 14:5808
Desplat V, Moreau S, Gay A, Belisle-Fabre S, Thiolat D, Massip S, Mossalayi D, Jarry C, Guillon J (2010) J Enzyme Inhib Med Chem 25:204
Desplat V, Moreau S, Belisle-Fabre S, Thiolat D, Uranga J, Lucas R, Massip S, de Moor L, Jarry C, Mossalayi D, Sonnet P, Déléris G, Guillon J (2011) J Enzyme Inhib Med Chem 26:657
Desplat V, Vincenzi M, Lucas R, Moreau S, Savrimoutou S, Pinaud N, Lesbordes J, Peyrilles E, Marchivie M, Routier S, Sonnet P, Rossi F, Ronga L, Guillon J (2016) Eur J Med Chem 113:214
Guillon J, Vincenzi M, Pinaud N, Ronga L, Rossi F, Savrimoutou S, Moreau S, Desplat V, Marchivie M (2016) Struct Chem Crystallogr Commun 2:18
Desplat V, Vincenzi M, Lucas R, Moreau S, Savrimoutou S, Rubio S, Pinaud N, Bigat D, Enriquez E, Marchivie M, Routier S, Sonnet P, Rossi F, Ronga L, Guillon J (2017) ChemMedChem 12:940
Barton DHR, Kervagoret J, Zard SZ (1990) Tetrahedron 46:7587
Alazard JP, Boye O, Gillet B, Guenard D, Beloeil JC, Thal C (1993) Bull Soc Chim Fr 130:779
Sheldrick GM (2008) Acta Crystallogr Sect A 64:112
Dolomanov OV, Bourhis LJ, Gildea RJ, Howard JAK, Puschmann H (2009) J Appl Crystallogr 42:339
Inaba S, Akatsu M, Hirohashi T, Yamamoto H (1976) Chem Pharm Bull 24:1076
Allen FH, Kennard O, Watson DG, Brammer L, Orpen AG, Taylor R (1987) J Chem Soc Perkin Trans 2: S1
Kanjana-opas A, Panphon S, Fun HK, Chantrapromma S (2006) Acta Crystallogr Sect E E62:o2728
Acknowledgements
This publication was supported by a grant from Ligue Contre le Cancer (Comité Aquitaine-Charentes, Bordeaux, France).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guillon, J., Moreau, S., Desplat, V. et al. Synthesis, Crystal Structure and Anti-leukemic Activity of 4-{4-[(4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl)benzyl]}-3-phenyl-3H-pyrrolo[2,3-c]quinoline. J Chem Crystallogr 49, 106–112 (2019). https://doi.org/10.1007/s10870-018-0734-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10870-018-0734-2